title: Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
abstract: Bleeding events have been observed among a subgroup of chronic lymphocytic leukaemia (CLL) patients treated with ibrutinib. We analysed data from two studies of single-agent ibrutinib to better characterize bleeding events and pattern of anticoagulation and antiplatelet use. Among 327 ibrutinib-treated patients, concomitant anticoagulation (11%) or antiplatelet use (34%) was common, but major bleeding was infrequent (2%). Bleeding events were primarily grade 1, and infrequently (1%) led to discontinuation. Among 175 patients receiving concomitant anticoagulant or antiplatelet agents, 5 had major bleeding events (3%). These events were typically observed in conjunction with other factors, such as coexisting medical conditions and/or concurrent medications.
authors.affiliation: Division of Hematology, The Ohio State University, Columbus, OH, USA.
authors.forename: Jeffrey A
authors.identifier: 0000-0001-9557-0820
authors.initials: JA
authors.lastname: Jones
authors.affiliation: The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, UK.
authors.forename: Peter
authors.initials: P
authors.lastname: Hillmen
authors.affiliation: Stanford University School of Medicine, Stanford, CA, USA.
authors.forename: Steven
authors.initials: S
authors.lastname: Coutre
authors.affiliation: Peter MacCallum Cancer Centre and St. Vincent's Hospital, Melbourne, Australia.
authors.forename: Constantine
authors.initials: C
authors.lastname: Tam
authors.affiliation: Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY, USA.
authors.forename: Richard R
authors.initials: RR
authors.lastname: Furman
authors.affiliation: Wilmot Cancer Center, University of Rochester, Rochester, NY, USA.
authors.forename: Paul M
authors.initials: PM
authors.lastname: Barr
authors.affiliation: Division of Hematology/Oncology, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA, USA.
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Schuster
authors.affiliation: University of California San Diego, Moores Cancer Center, La Jolla, CA, USA.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Kipps
authors.affiliation: Sarah Cannon Research Institute, Nashville, TN, USA.
authors.forename: Ian W
authors.initials: IW
authors.lastname: Flinn
authors.affiliation: Medical University of Vienna, Vienna, Austria.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Jaeger
authors.affiliation: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Jan A
authors.initials: JA
authors.lastname: Burger
authors.affiliation: Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
authors.forename: Mei
authors.initials: M
authors.lastname: Cheng
authors.affiliation: Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
authors.forename: Joi
authors.initials: J
authors.lastname: Ninomoto
authors.affiliation: Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
authors.forename: Danelle F
authors.initials: DF
authors.lastname: James
authors.affiliation: Division of Hematology, The Ohio State University, Columbus, OH, USA.
authors.forename: John C
authors.initials: JC
authors.lastname: Byrd
authors.affiliation: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.|University of California Irvine, Irvine, CA, USA.
authors.forename: Susan M
authors.initials: SM
authors.lastname: O'Brien
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D019983:Guideline Adherence; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D010880:Piperidines; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D010976:Platelet Count; D017410:Practice Guidelines as Topic; D011720:Pyrazoles / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*
chemical_list: D000925:Anticoagulants; D000970:Antineoplastic Agents; D010880:Piperidines; D010975:Platelet Aggregation Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D000225:Adenine
keywords: anticoagulation; bleeding; chronic lymphocytic leukaemia; haemorrhage; ibrutinib